Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
Recruiting · NCT06864936 · Registry updated 2026-07-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Not applicable | 2026-07-29 | NCT06864936 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| TG Therapeutics, Inc. | 16 |
| University of Maryland, Baltimore | 198 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Maryland, Baltimore | Baltimore | United States | 32 |